Periodic Reporting for period 1 - PeptiCHIP (Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization)

Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The core of immunotherapy stands in identifying tumour-specific fingerprints – the neoantigens – that are peptides expressed uniquely by cancer cells, capable...